natgillin/translations-raw huggingface dataset:
Severe hepatic impairment (Child-Pugh classification C) or severe renal impairment (creatinine clearance < 30 ml/min).
Huda jetrna (Child-Pughova klasifikacija C) ali huda ledvična okvara (očistek kreatinina < 30 ml/min).
Severe hepatic impairment (see also section 4.2)
hudo okvaro jeter (glejte tudi poglavje 4.2),
Severe hepatic impairment (see sections 4.2, 4.4 and 5.2).
Huda okvara jeter (glejte poglavja 4.2, 4.4 in 5.2).
Severe hepatic impairment (see sections 4.4 and 5.2).
Huda jetrna okvara (glejte poglavji 4.4 in 5.2).
Severe hepatic impairment (serum albumin <25 g/l or Child-Pugh score  10).
za bolnike s hudo okvaro jeter (albumin v serumu < 25 g/l ali ocena ≥ 10 po Child-Pughu),
Severe hepatic impairment (total bilirubin >3 x ULN).
Huda okvara jeter (celokupni bilirubin >3-kratna ZNM).
Severe hepatic impairment [Child-Pugh Class C (see sections 4.2, 4.4 and 5.2)].
Huda okvara jeter [Child-Pugh razred C (glejte poglavja 4.2, 4.4 in 5.2)].
Severe hepatic impairment including biliary cirrhosis or active liver disease including unexplained persistent elevations in liver function tests (including serum transaminase elevation) exceeding 3 fold the upper limit of normal (ULN) (see section 4.4).
Huda okvara jeter, v katero sta všteti tudi biliarna ciroza in aktivna jetrna bolezen, vključno z nepojasnjenimi trajno zvišanimi vrednostmi parametrov pri testih jetrne funkcije (vključno z zvišano serumsko transaminazo), ki so višje od trikratne zgornje meje normalnih vrednosti (ZMN) (glejte poglavje 4.4).
Severe hepatic impairment,
hudo okvaro jeter,
Severe hepatic impairment, biliary cirrhosis and cholestasis
Huda jetrna okvara, biliarna ciroza ali holestaza
Severe hepatic impairment, biliary cirrhosis and cholestasis
Huda jetrna okvara, biliarna ciroza ali holestaza+
Severe hepatic impairment, biliary cirrhosis and cholestasis (see section 4.2).
Huda okvara jeter, biliarna ciroza ali holestaza (glejte poglavje 4.2).
Severe hepatic impairment, biliary cirrhosis or cholestasis.
Huda okvara jeter, biliarna ciroza ali holestaza.
Severe hepatic impairment, biliary cirrhosis or cholestasis.
Huda okvara jeter, npr. biliarna ciroza ali holestaza.
Severe hepatic impairment.
huda jetrna okvara
Severe hepatic impairment.
huda jetrna okvara,
Severe hepatic impairment.
huda okvara jeter
Severe hepatic impairment.
Hudo okvaro jeter.
Severe hepatic insufficiency
hudo jetrno popuščanje
Severe hepatic insufficiency.
Bolniki s hudo insuficienco jeter.
Severe hepatitis and liver failure (see section 4.4)
hud hepatitis in odpoved jeter (glejte poglavje 4.4)
Severe HI
Huda OJ
Severe high blood pressure.
zelo visok krvni tlak
Severe hives/nettle rash
hudo koprivnico/urtikarijo
Severe humoral or cellular (primary or acquired) immunodeficiency, e.g. severe combined immunodeficiency, agammaglobulinemia and AIDS or symptomatic HIV infection or an age-specific CD4+ T-lymphocyte percentage in children below 12 months: CD4+ <25% %; children between 12- 35 months: CD4+ < 20%; children between 36-59 months: CD4+ < 15% (see section 4.4).
Huda humoralna ali celična (primarna ali pridobljena) imunska pomanjkljivost, npr. huda kombinirana imunska pomanjkljivost, agamaglobulinemija in AIDS ali simptomatska okužba s HIV ali za starost specifični odstotek CD4+ T-limfocitov pri otrocih do 12 mesecev: CD4+ < 25 %; pri otrocih med 12 in 35 meseci: CD4+ < 20 %; pri otrocih med 36 in 59 meseci: CD4+ < 15 % (glejte poglavje 4.4).
Severe hyperglycaemia or ketoacidosis must always be treated by a doctor, normally in a hospital.
Hudo hiperglikemijo ali ketoacidozo mora vedno zdraviti zdravnik, navadno v bolnišnici.
Severe hypersensitivity (e.g., anaphylactic reaction, severe skin reaction) to any other type of beta-lactam antibacterial agent (e.g., penicillins or carbapenems).
Huda preobčutljivost (npr. anafilaktična reakcija, huda kožna reakcija) na katero koli drugo vrsto betalaktamskih antibiotikov (npr. na peniciline ali karbapeneme).
Severe hypersensitivity (e.g., anaphylactic reaction, severe skin reaction) to any other type of beta-lactam antibacterial agent (e.g., penicillins or cephalosporins).
Huda preobčutljivost (npr. anafilaktična reakcija, huda kožna reakcija) za kateri koli drug betalaktamski antibiotik (npr. za peniciline ali cefalosporine).
Severe hypersensitivity reactions (including bronchospasm, dyspnoea, angioedema, and anaphylaxis) (see sections 4.3 and 4.4)
hudih preobčutljivostnih reakcij (vključno z bronhospazmom, dispnejo, angioedemom in anafilaksijo) (glejte poglavji 4.3 in 4.4)
Severe hypersensitivity reactions to the active substance or to any of the excipients listed in section 6.1.
Huda preobčutljivostna reakcija na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1.
Severe hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Huda preobčutljivost na učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1.
Severe hypersensitivity, including anaphylaxis, has been observed in clinical trials with Perjeta (see section 4.8).
V kliničnih preskušanjih z zdravilom Perjeta so opazili hudo preobčutljivost, vključno z anafilaksijo (glejte poglavje 4.8).
Severe hypertension (>200 mmHg systolic or 110 mmHg diastolic) occurred in 4.7% of patients with solid tumours.
Huda hipertenzija (sistolični tlak > 200 mmHg ali diastolični tlak > 110 mmHg) se je pojavila pri 4,7 % bolnikov s čvrstimi tumorji.
Severe hypertension occurred in 10% of pNET patients on sunitinib and 3% of patients on placebo.
Do hude hipertenzije je prišlo pri 10 % bolnikov s pNET, ki so prejemali sunitinib, in pri 3 % bolnikov, ki so prejemali placebo.
Severe hypertension occurred in 12% of treatment-naïve patients on sunitinib and <1% of patients on IFN-.
Huda hipertenzija se je pojavila pri 12 % predhodno nezdravljenih bolnikov, ki so prejemali sunitinib, ter pri < 1 % bolnikov, ki so prejemali IFN-.
Severe hypoglycaemia
Hude hipoglikemije
Severe hypoglycaemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death.
Huda hipoglikemija lahko povzroci nezavest, konvulzije ali oboje in ima lahko za posledico prehodno ali trajno okvaro delovanja možganov ali celo smrt.
Severe hypoglycaemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death.
Težka hipoglikemija lahko povzroči nezavest in/ali konvulzije, začasno ali trajno okvaro delovanja možganov ali celo smrt.
Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated by glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a person who has received appropriate instruction, or by glucose given intravenously by a medical professional.
Hude hipoglikemije, ko je bolnik nezavesten, je mogoce zdraviti z glukagonom (0,5 do 1 mg), ki ga da ustrezno poducena oseba intramuskularno ali subkutano ali z glukozo, ki jo da zdravstveni delavec intravensko.
Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated with glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a trained person, or with glucose given intravenously by a healthcare professional.
Hude hipoglikemije, ko je bolnik nezavesten, je mogoče zdraviti z glukagonom (0,5 do 1 mg), ki ga da intramuskularno ali subkutano ustrezno podučena oseba, ali z glukozo, ki jo da intravensko zdravstveni delavec.
Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated with glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a trained person, or with glucose given intravenously by a healthcare professional.
Hude hipoglikemije, ko je bolnik nezavesten, je mogoče zdraviti z glukagonom (0,5 do 1 mg), ki ga intramuskularno ali subkutano aplicira ustrezno podučena oseba, ali z glukozo, ki jo intravensko aplicira zdravstveni delavec.
Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated with glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a trained person, or with glucose given intravenously by a healthcare professional.
Hude hipoglikemije, ko je bolnik nezavesten, je mogoče zdraviti z glukagonom (0,5 do 1 mg), ki ga intramuskularno ali subkutano aplicira ustrezno poučena oseba, ali z glukozo, ki jo intravensko aplicira zdravstveni delavec.
Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated with glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a trained person, or with glucose given intravenously by a healthcare professional.
Hude hipoglikemije, ko je bolnik nezavesten, se lahko zdravi z glukagonom (0,5 do 1 mg), ki ga intramuskularno ali subkutano aplicira ustrezno podučena oseba, ali z glukozo, ki jo intravensko aplicira zdravstveni delavec.
Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated with glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a trained person, or with glucose given intravenously by physicians or other healthcare staff.
Hude hipoglikemije, ko je bolnik nezavesten, je mogoče zdraviti z glukagonom (0,5 do 1 mg), ki ga intramuskularno ali subkutano aplicira ustrezno podučena oseba, ali z glukozo, ki jo intravensko aplicira zdravnik ali drugo zdravstveno osebje.
Severe hypoglycaemic episodes, where the patient is not able to treat himself, can be treated with glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a trained person, or with glucose given intravenously by a healthcare professional.
Hude epizode hipoglikemije, kjer si bolnik sam ne more pomagati, je mogoče zdraviti z glukagonom (0,5 do 1 mg), ki ga intramuskularno ali subkutano aplicira ustrezno poučena oseba, ali z glukozo, ki jo intravensko aplicira zdravstveni delavec.
Severe hypoglycaemic episodes, where the patient is not able to treat himself, can be treated with glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a trained person, or with glucose given intravenously by a healthcare professional.
Hude epizode hipoglikemije, pri katerih si bolnik sam ne more pomagati, je mogoče zdraviti z glukagonom (0,5 do 1 mg), ki ga intramuskularno ali subkutano aplicira ustrezno poučena oseba, ali z glukozo, ki jo intravensko aplicira zdravstveni delavec.
severe hypoproteinaemia (low blood protein levels).
bolniki s hudo hipoproteinemijo (nizko ravnjo beljakovin v krvi).
severe hypoproteinaemia (low blood protein levels).
s hudo hipoproteinemijo (nizko ravnjo beljakovin v krvi).
Severe hypotension
huda hipotenzija,
Severe hypotension.
huda hipotenzija;
severe immunodeficiency states, such as acquired immune deficiency syndrome (AIDS);
bolniki s hudo imunsko pomanjkljivostjo, kot je sindrom pridobljene imunske pomanjkljivosti (AIDS);
severe immunodeficiency states, such as acquired immune deficiency syndrome (AIDS);
hudo imunsko pomanjkljivostjo, kot je sindrom pridobljene imunske pomanjkljivosti (aids),
Severe increase in blood pressure (hypertensive crisis).
Izrazito povišanje krvnega tlaka (hipertenzivna kriza).
Severe increase in blood pressure.
resno zvišanje krvnega tlaka
Severe increase in blood pressure.
resno zvišanje krvnega tlaka,
Severe infection
hudih okužbah;
Severe infection (sepsis).
Huda okužba (sepsa).
Severe infections (including sepsis), which may be fatal.
hude okužbe (vključno s sepso), ki so lahko usodne,
Severe infections may lead to kidney problems, which can put you at risk for lactic acidosis (see 'Warnings and precautions'). if you have lost a lot of water from your body (dehydration), e.g. due to long-lasting or severe diarrhoea, or if you have vomited several times in a row.
Hude okužbe lahko privedejo do težav z ledvicami, kar lahko predstavlja tveganje za nastanek laktacidoze (glejte 'Opozorila in previdnostni ukrepi'). če ste izgubili veliko vode (dehidracija), npr. zaradi dolgotrajne ali hude driske ali večkratnega zaporednega bruhanja.
Severe infections may lead to kidney problems, which can put you at risk for lactic acidosis (see 'Warnings and precautions'); if you have lost a lot of water from your body (dehydration), e.g. due to long-lasting or severe diarrhoea, or if you have vomited several times in a row.
Hude okužbe lahko privedejo do težav z ledvicami, kar lahko predstavlja tveganje za nastanek laktacidoze (glejte 'Opozorila in previdnostni ukrepi'); če ste izgubili veliko vode (dehidracija), npr. zaradi dolgotrajne ali hude driske ali večkratnega zaporednega bruhanja.
Severe infections of the gingival and periodontal tissues in dogs:
Resna vnetja dlesni in periodontalnega tkiva pri psih:
Severe infections such as pneumonia
hude okužbe kot je pljučnica
Severe infections, including fatal cases, have been reported in SLE patients receiving immunosuppressant therapy, including belimumab (see section 4.8).
Pri bolnikih s SLE, ki so prejemali imunosupresivna zdravila (vključno z belimumabom), so bile opisane hude okužbe, tudi s smrtnim izidom (glejte poglavje 4.8).
Severe infections, with or without neutropenia, have included pneumonia, sepsis, and cellulitis.
Hude okužbe z nevtropenijo ali brez nje so vključevale pljučnico, sepso in celulitis.
Severe infusion-related reactions have been reported in patients receiving pembrolizumab (see section 4.8).
Pri bolnikih, ki so prejemali pembrolizumab, so poročali o hudih z infuzijo povezanih reakcijah (glejte poglavje 4.8).
Severe IRRs (such as bronchospasm, hypotension) occurred in up to 12% of the cases.
Hude reakcije, povezane z infuzijo (npr. bronhospazem, hipotenzija), so se pojavile pri do 12 % bolnikov.
Severe IRRs with fatal outcome have been reported in the post-marketing setting.
V obdobju trženja so poročali o resnih, z infuzijo povezanih reakcijah, ki so se končale s smrtjo.
Severe kidney impairment (will normally be determined by your doctor with certain specific blood tests).
Huda okvara ledvic (to zdravnik po navadi ugotovi zdravnik z določenimi specifičnimi preiskavami krvi).
Severe kidney problems
Hude ledvične težave
Severe lameness/musculoskeletal disorder
Močno šepanje/mišično skeletne motnje
Severe lameness/musculoskeletal disorder.
močno šepanje/mišično lokomotorne motnje
Severe liver function test abnormalities (Grade 3 to 4) and hepatic dysfunction with clinical manifestations (including fatal outcomes) have been reported in a small proportion of patients (see section 4.8).
Pri majhnem deležu bolnikov so poročali o hudih nenormalnostih izvidov preiskav delovanja jeter (stopnje 3 do 4) in motenem delovanju jeter s kliničnimi znaki (vključno s smrtnimi izidi) (glejte poglavje 4.8).
Severe liver impairment (Child-Pugh class C).
Huda okvara jeter (Child-Pugh stopnje C).
Severe liver impairment.
Huda jetrna okvara.
Severe liver injury*#
huda okvara jeter*#
Severe liver problems leading to liver failure and inflammation of the brain.
hude težave z jetri, ki povzročijo odpoved jeter in vnetje možganov
Severe liver problems: the dose may be reduced to one tablet (200 mg of lumacaftor/125 mg of ivacaftor) every 12 hours
Resne težave z jetri: odmerek se lahko zmanjša na eno tableto (200 mg lumakaftorja in 125 mg ivakaftorja) na 12 ur.
Severe liver toxicity was observed in dogs treated for 2weeks, with elevated liver enzymes, hepatocellular necrosis, bile duct necrosis, and bile duct hyperplasia.
Pri psih, ki so zdravilo dobivali po 2 tedna, so opazili hudo toksičnost za jetra z zvišanimi jetrnimi encimi, hepatocelularno nekrozo, nekrozo žolčevodov in hiperplazijo žolčevodov.
Severe lymphoedema of the limb.
Hud limfedem okončine
Severe malaria according to WHO definition.
Huda malarija po definiciji SZO.
Severe mental problems (which in very rare cases may lead to self-harm)
hude duševne težave (ki lahko v zelo redkih primerih povzročijo samopoškodovanje)
Severe mucocutaneous reactions
Hude reakcije kože in sluznic
Severe nephritis and renal dysfunction have been observed with monotherapy treatment or nivolumab in combination with ipilimumab (see section 4.8).
Pri zdravljenju z nivolumabom v monoterapiji ali zdravljenju z nivolumabom v kombinaciji z ipilimumabom so poročali o hudem nefritisu in okvari delovanja ledvic (glejte poglavje 4.8).
Severe neurological side effects have been reported with the use of Atriance.
Pri zdravljenju z zdravilom Atriance so poročali o pojavu resnih nevroloških neželenih učinkov.
Severe neurological side effects have been reported with the use of DepoCyte.
Poročali so o hudih nevroloških stranskih učinkih pri uporabi zdravila DepoCyte.
Severe neurological toxicity can manifest as coma, status epilepticus, demyelination, or ascending neuropathy similar in appearance to Guillain- Barré syndrome (see section 4.8).
Posledice hude nevrološke toksičnosti so lahko koma, epileptični status, demielinizacija ali ascendentna nevropatija, podobna Guillain- Barréjevemu sindromu (glejte poglavje 4.8).
Severe neutropenia (see section 4.4)
huda nevtropenija (glejte poglavje 4.4)
Severe neutropenia lasted beyond seven days in 11 % of courses overall.
Huda nevtropenija je pri 11 % vseh ciklov zdravljenja trajala več kot
Severe neutropenia lasted beyond seven days in 11 % of courses overall.
Huda nevtropenija je pri 11 % vseh ciklov zdravljenja trajala več kot 7 dni.
Severe neutropenia lasted on average for 1.4 days which compared with 1.6 days and 1.8 days reported in studies using filgrastim found in the literature.
Huda nevtropenija je v povprečju trajala 1,4 dneva, kar je primerljivo z 1,6 dneva in 1,8 dneva, zabeleženih v študijah iz literature, v katerih so uporabljali filgrastim.
Severe neutropenia may be managed by the use of G-CSF or equivalent at the physician’s discretion in accordance with relevant guidelines.
Hudo nevtropenijo lahko zdravnik zdravi z uporabo G-CSF ali enakovrednim zdravilom po presoji zdravnika v skladu z ustreznimi smernicami.
Severe neutropenia may be managed by the use of granulocyte colony-stimulating factor (G-CSF) or equivalent at the physician’s discretion in accordance with relevant guidelines (see section 5.1).
Hudo nevtropenijo lahko zdravnik zdravi z uporabo granulocitne kolonije stimulirajočega faktorja (G- CSF-granulocyte colony-stimulating factor,) ali enakovrednim zdravilom po presoji zdravnika v skladu z ustreznimi smernicami (glejte poglavje 5.1).
severe or life threatening skin reaction including blisters (Stevens Johnson syndrome, toxic epidermal necrolysis)
hude ali smrtno nevarne kožne reakcije, vključno z mehurji (Stevens-Johnsonov sindrom, toksična epidermalna nekroliza)
Severe or life- threatening rash considered related to nevirapine treatment occurred in 1.1 % of patients during the lead-in phase with Viramune immediate-release.
Hud ali življenjsko nevaren izpuščaj, ki je bil predvidoma povezan z zdravljenjem z nevirapinom, se je pojavil pri 1,1 % bolnikov, ki so med uvajalnim zdravljenjem jemali zdravilo Viramune s takojšnjim sproščanjem.
Severe or life-threatening hypersensitivity to the active substance or to any of the excipients if hypersensitivity is not controllable.
Huda ali smrtno nevarna preobčutljivost na zdravilno učinkovino ali katero koli pomožno snov, če preobčutljivosti ni mogoče nadzorovati.
Severe or uncontrollable bleeding with symptoms such as: vomiting blood, black stolls, bloody urine, headache, coughing up of blood.
resna ali nenadzorovana krvavitev s simptomi, kot so: bruhanje krvi, črno blato, krvav urin, glavobol, izkašljevanje krvi.
Severe osteoarthritis of the knee.
Hud osteoartritis kolena.
Severe pain and swelling in your joints – these are signs of gout
hude bolečine in oteklost sklepov - to so znaki protina
Severe pain in the lower abdomen and pelvic area that may be sharp, with menstrual irregularities (ovarian cyst)
hude bolečine v spodnjem delu trebuha in predelu medenice, ki so lahko ostre in jih spremljajo motnje menstrualnega ciklusa (cista na jajčniku)
Severe penile haematoma was also reported as an adverse reaction in 39 of 1044 patients (3.7%) in the controlled and uncontrolled clinical studies in Peyronie’s disease.
O hudem hematomu penisa kot neželenem učinku so poročali pri 39 od 1.044 bolnikov (3,7 %) v nadzorovanih in nenadzorovanih kliničnih študijah pri Peyroniejevi bolezni.
Severe peripheral arterial circulatory disturbances (Raynaud’s phenomenon)
Hude motnje perifernega arterijskega obtoka (Raynaudov fenomen)
Severe psoriasis in patients from the age of 6 years who have had an inadequate response to (or are unable to take) phototherapies or other systemic therapies.
za zdravljenje hude psoriaze pri bolnikih, starejših od 6 let, ki so se nezadostno odzvali na fototerapije ali druge sistemske terapije (ali jih niso prenašali).
Severe psychiatric and central nervous system effects (such as depression, suicidal ideation, attempted suicide and aggressive behaviour, etc.)
hudi psihiatrični učinki in učinki na osrednje živčevje (kot so depresija, samomorilne misli, poskus samomora in agresivno vedenje itd.);
Severe pulmonary adverse reactions occur in association with the use of Herceptin and have been associated with a fatal outcome.
V povezavi z uporabo zdravila Herceptin se pojavljajo hudi pljučni neželeni učinki, ki so bili povezani tudi s smrtnim izidom.
Severe pulmonary dysfunction.
Hude motnje pljučne funkcije
Severe rash
Hud izpuščaj
Severe rash, hives or other signs of allergic reaction
hud izpuščaj, koprivnico ali druge znake alergijske reakcije
Severe rash, hives or other signs of allergic reaction;
hud izpuščaj, koprivnico ali druge znake alergijske reakcije;
Severe rash: Extent of rash > 50% of body surface area or associated with vesicles, bullae, ulcerations other than SJS
Hud izpuščaj: obsega > 50% telesne površine ali je povezan z mehurčki, mehurji, razjedami, ki niso povezane s SJS
Severe rash;
hud izpuščaj
Severe reactions, possibly fatal, involving the heart and blood vessels may occur.
Pojavijo se lahko hudi zapleti na srcu in ožilju, ki so lahko usodni.
Severe reduced visual acuity2, visual impairment such as reduced visual acuity, blurred, fuzzy vision, or photopsia, visual field defect such as scotoma, grey or dark haloes and black spots.
zelo zmanjšana ostrina vida2, motnje vida, kot so zmanjšana ostrina vida, zamegljen, zabrisan vid, fotopsija, izpadi vidnega polja, na primer skotomi, sivi ali temni obroči in črne pege
Severe reduction in blood cells which can cause weakness, bruising or make infections more likely.
hudo zmanjšanje števila krvnih celic, kar lahko povzroči slabotnost, modrice ali poveča možnost infekcij,
Severe reduction in certain blood cells leading to increased risk of bleeding or bruising, increased risk of infections, pale skin and extreme tiredness
veliko zmanjšanje števila določenih krvnih celic, kar vodi do povečanega tveganja za pojav krvavitev ali odrgnin, okužb, bledosti kože in hudo utrujenost,
Severe reduction in the number of white blood cells, which makes infections more likely (leucopenia).
hudo zmanjšanje števila belih krvnih celic, kar lahko poveča možnosti infekcij (levkopenija),
Severe reduction of insulin effects (insulin resistance)
hudo zmanjšanje učinka insulina (rezistenca na insulin)
Severe renal and/or hepatic impairment.
Huda ledvična in/ali jetrna okvara.
Severe renal function disorders (creatinine clearance < 30 ml/min)
hudih motnjah ledvičnega delovanja (očistek kreatinina < 30 ml/min)
Severe renal impairment
Hudo okvarjeno delovanje ledvic
Severe renal impairment (10-29 ml/min)
Huda ledvična okvara (10 -29 ml/min)
Severe renal impairment (CLcr < 30 mL/min, not requiring dialysis)
(CLcr < 30 ml/min, dializa ni potrebna)
Severe renal impairment (CrCl <30 ml/min)
Huda okvara ledvic (očistek kreatinina < 30 ml/min).
Severe renal impairment (CrCl <30 ml/min).
Hudo okvaro ledvic (očistek kreatinina < 30 ml/min).
Severe renal impairment (CrCl <30ml/min) and haemodialysis patients
Huda ledvična okvara (CrCl < 30 ml/min) in bolniki na hemodializi
Severe renal impairment (CrCl below 30 ml/min)
Huda ledvična okvara (CrCl pod 30 ml/min)
Severe renal impairment (CrCl below 30 mL/min) or end stage renal disease
Huda ledvična okvara (očistek kreatinina pod 30 ml/min) ali končna stopnja ledvične bolezni Uporaba zdravila ni priporočljiva pri bolnikih s hudo ledvično okvaro ali končno stopnjo ledvične bolezni.
Severe renal impairment (creatinine clearance < 30 ml/min)
Huda ledvična okvara (kreatininski očistek < 30 ml/min).